|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
We analyzed angiographic results at follow up (including binary angiographic restenosis [BAR] and late-lumen-loss [LLL]) and clinical outcomes in hospital and at follow up, including target lesion revascularization (TLR), cardiovascular-, and all-cause mortality, myocardial infarction (MI) and stent thrombosis (ST).
|
30467994 |
2019 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
This study was undertaken to explore the relationship between LV remodeling after myocardial infarction and polymorphisms in the cardiac β1-AR and β2-AR genes.
|
21626217 |
2011 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The Gln(27)Glu polymorphism but not the Arg(16)Gly polymorphism of the beta2-adrenergic receptor (ADRB2) gene appears to be associated with a broad range of aging-associated phenotypes, including cancers at different sites, myocardial infarction (MI), intermittent claudication (IC), and overall/healthy longevity in the Framingham Heart Study Offspring cohort.
|
20399803 |
2010 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that effects of single specific genetic variants of the ADRB2 and ACE genes on MI can be readily altered by gene-gene or/and gene-environmental interactions, especially in large heterogeneous samples.
|
20230274 |
2010 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
Association between polymorphisms in the beta2-adrenergic receptor gene with myocardial infarction and ischaemic stroke in women.
|
19190821 |
2009 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Association of beta-1 and beta-2 adrenergic receptor gene polymorphisms with myocardial infarction.
|
19623647 |
2009 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the relationship between ADRB1 and ADRB2 haplotypes, cardiovascular risk (death, nonfatal myocardial infarction (MI), and nonfatal stroke), and atenolol-based vs. verapamil sustained-release (SR)-based antihypertensive therapy in 5,895 coronary artery disease (CAD) patients.
|
18615004 |
2008 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Of the 92 polymorphisms tested, three that we previously reported on were associated with risk of MI, [pro12ala in the peroxisome proliferator activated-receptor gamma gene (odds ratio, OR = 0.75, P = 0.02); thr164ile in the beta-2 adrenergic receptor gene (OR = 0.14, P = 0.007); and ala23thr polymorphism in the eotaxin gene (OR = 1.87, P = 0.01)].
|
16420563 |
2006 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The present study found no evidence that haplotype for the two most common polymorphisms in the beta2AR are associated with development of MI in a Swedish hypertensive population, but haplotype may be associated with SBP.
|
15931235 |
2005 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
Haplotype analysis of the beta2 adrenergic receptor gene and risk of myocardial infarction in humans.
|
15520258 |
2005 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
RGD |
Potent adenylate cyclase agonist forskolin restores myoprotective effects of ischemic preconditioning in rat hearts after myocardial infarction.
|
12400771 |
2002 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Four ADRB2 gene polymorphisms C19R (T-47C), T-20C, G16R (G+46A), Q27E (C+79G) were investigated in two studies: PEGASE, a study of moderate to severe hypertension (707 cases) conducted in France, and ECTIM, a case-control study of MI (1178 cases, 1187 controls) conducted in France, Northern Ireland and Scotland.
|
11821707 |
2002 |